Home › Targets › CD3
CD3 (5 companies · 20 programs)
Companies with an active program directed at CD3.
- VIR-5500 — Metastatic Castration-Resistant Prostate Cancer Phase 1
- VIR-5818 — Breast Cancer Phase 1
- VIR-5818 — Colorectal Cancer Phase 1
- VIR-5525 — Non-Small Cell Lung Cancer Phase 1
- VIR-5525 — Colorectal Cancer Phase 1
- VIR-5525 — Head and Neck Squamous Cell Carcinoma Phase 1
- VIR-5525 — Cutaneous Squamous Cell Carcinoma Phase 1
- VIR-5500 — Metastatic Hormone-Sensitive Prostate Cancer Phase 1
- CLN-978 — Systemic Lupus Erythematosus Phase 1
- CLN-978 — Rheumatoid Arthritis Phase 1
- CLN-978 — Sjögren's Disease Phase 1
- velinotamig — Systemic Lupus Erythematosus Phase 1
- CLN-049 — Acute Myeloid Leukemia Phase 1
- CLN-049 — Myelodysplastic Syndrome Phase 1
- JANX007 — Metastatic Castration-Resistant Prostate Cancer Phase 1
- JANX008 Phase 1
- JANX011 Phase 1
- ADG138 Preclinical
- ADG152 Preclinical
